New calls from Russian patient organizations on vital drugs shortages

The situation with the availability of modern, original drugs continues to deteriorate in Russia, which is mainly due to ever-tightening sanctions against the country and its growing isolation in the international arena, reports The Pharma Letter’s local correspondent.

An example of this is Pulmozyme (dornase alfa), a drug for the treatment of cystic fibrosis, which was supplied to the Russian market by Swiss pharma giant Roche (ROG: SIX).

Recently representatives of numerous patient organizations, such as Help for Patients with Cystic Fibrosis, have complained about the lack of Pulmozyme in the domestic market. According to them, the available analogue, is not suitable for every patient.